Daiwa Securities Group Inc. Halozyme Therapeutics, Inc. Transaction History
Daiwa Securities Group Inc.
- $27.1 Billion
- Q2 2025
A detailed history of Daiwa Securities Group Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 4,025 shares of HALO stock, worth $258,002. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,025
Previous 395
918.99%
Holding current value
$258,002
Previous $25,000
736.0%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding HALO
# of Institutions
609Shares Held
126MCall Options Held
408KPut Options Held
388K-
Black Rock Inc. New York, NY17.6MShares$1.13 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$785 Million0.01% of portfolio
-
State Street Corp Boston, MA5.94MShares$380 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA3.47MShares$222 Million0.03% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.4MShares$218 Million3.92% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.93B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...